17 April 2025
17 April 2025
Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.
The executive order aims to lower prescription prices, but targets the mechanism for negotiating small molecule drug costs.
Leveraging Trump鈥檚 impending tariffs, pharma companies have called on Europe again to change regulation, threatening a US exodus.
Our editorial team dissects the latest developments in the ongoing story of how evolving US tariffs could impact the healthcare sector.
Rival bidder Ayrmid has failed to deliver a binding, fully financed proposal by the agreed date.
The agreement is seen as a win for global health ahead of the US withdrawal from the WHO and amidst foreign aid cuts by the US government.
Glycomine鈥檚 Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.
The spray leverages transmucosal absorption enhancement technology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
